<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28565">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734862</url>
  </required_header>
  <id_info>
    <org_study_id>CD101.IV.2.03</org_study_id>
    <secondary_id>2015-005599-51</secondary_id>
    <nct_id>NCT02734862</nct_id>
  </id_info>
  <brief_title>STRIVE: CD101 Compared to Caspofungin Followed by Oral Step Down Treatment in Subjects With Candidemia</brief_title>
  <official_title>STRIVE: A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed By Oral Fluconazole Step-down in the Treatment of Subjects With Candidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cidara Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cidara Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if intravenous CD101 is safe and effective in the
      treatment of candidemia when compared to caspofungin (followed by oral fluconazole).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events [safety and tolerability]</measure>
    <time_frame>Day 45- 52</time_frame>
    <description>Number of subjects with treatment emergent adverse events, clinical chemistry and hematology laboratory tests, vital signs, physical exams, and ECG abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mycological eradication</measure>
    <time_frame>Day 14 (+/- 1 day)</time_frame>
    <description>Number of subjects with negative blood culture(s) for yeast or Candida and no change of antifungal therapy for treatment of candidemia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resolution of systemic signs attributable to candidemia</measure>
    <time_frame>Day 14 (+/- 1 day)</time_frame>
    <description>Number of subjects with complete resolution of all systemic signs of candidemia which were present at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mycological eradication</measure>
    <time_frame>Day 5</time_frame>
    <description>Number of subjects with negative blood culture(s) for yeast or Candida and no change of antifungal therapy for treatment of candidemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of systemic signs attributable to candidemia</measure>
    <time_frame>Day 5</time_frame>
    <description>Number of subjects with complete resolution of all the systemic signs of candidemia which were present at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of systemic signs attributable to candidemia</measure>
    <time_frame>Day 45-52</time_frame>
    <description>Number of subjects with complete resolution of all the systemic signs of candidemia which were present at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological eradication</measure>
    <time_frame>Day 45-52</time_frame>
    <description>Number of subjects with negative blood culture(s) for yeast or Candida and no change of antifungal therapy for treatment of candidemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Day 14 (+/- 1 day)</time_frame>
    <description>Number of subjects alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Day 45-52</time_frame>
    <description>Number of subjects alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical signs and symptoms</measure>
    <time_frame>Day 14 (+/- 1 day)</time_frame>
    <description>Subjects with no new clinical signs or symptoms attributable to candidemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical signs and symptoms</measure>
    <time_frame>Day 45-52</time_frame>
    <description>Subjects with no new clinical signs or symptoms attributable to candidemia</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Candidemia</condition>
  <condition>Mycoses</condition>
  <condition>Fungal Infection</condition>
  <condition>Fungemia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four hundred milligrams (400 mg) CD101 administered as a 60 minute infusion once weekly for 2 weeks with optional 3rd dose as medically indicated.
Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four hundred milligrams (400 mg) CD101 administered as a 60 minute infusion once for 1st week followed by two hundred milligrams (200 mg) administered as a 60 minute infusion once weekly for 2nd week and optional 3rd week as medically indicated.
Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as oral step down.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Seventy milligrams (70 mg) single loading dose of caspofungin administered as a 60 minute infusion followed by fifty milligrams (50 mg) daily maintenance 60 minute infusion for at least 3 up to 21 days as medically indicated or until subject eligible for oral step-down.
Eight hundred milligrams (800 mg) single loading dose oral fluconazole step-down therapy followed by four hundred milligrams (400 mg) maintenance dose beginning on Day 4 if subject is eligible up to Day 14 or Day 21 as medically indicated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD101</intervention_name>
    <description>Intravenous antifungal therapy</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>CD101 Injection</other_name>
    <other_name>CD101 for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caspofungin</intervention_name>
    <description>Intravenous antifungal therapy</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Cancidas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>oral antifungal therapy</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>generic fluconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous placebo</intervention_name>
    <description>normal saline</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>placebo infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral placebo</intervention_name>
    <description>microcrystalline cellulose</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>encapsulated cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mycological diagnosis of candidemia (at least 1 blood culture positive for Candida or
             positive test for Candida from a sponsor approved rapid diagnostic test)

          -  life expectancy of greater than 72 hours

          -  female subjects of child bearing potential &lt;2 years post menopausal must agree to one
             barrier method and one highly effective method of birth control or sexual abstinence.

          -  male subjects must agree to use one barrier method of birth control or sexual
             abstinence

          -  provide informed consent

          -  presence of one or more systemic signs attributable to candidemia

        Exclusion Criteria:

          -  documented or suspected invasive candidiasis including intra-abdominal infection,
             endocarditis, osteomyelitis, meningitis, or endophthalmitis

          -  neutropenia

          -  alanine aminotransferase or aspartate aminotransferase levels &gt;10 fold the upper
             limit of normal

          -  severe hepatic impairment in subjects with a history of chronic cirrhosis

          -  greater than 48 hours systemic antifungal treatment at approved doses to treat
             candidemia

          -  pregnant or lactating females who are nursing

          -  known hypersensitivity to CD101, caspofungin, any echinocandin, or to any of their
             excipients

          -  previous participation in this or any previous CD101 study

          -  recent use of an investigational medicinal product within 28 days of first dose of
             study drug or presence of an investigational device at the time of screening

          -  Principal Investigator considers the subject should not participate

          -  presence of indwelling vascular catheter or device that cannot be removed and is
             likely to be the source of candidemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taylor Sandison, MD MPH</last_name>
    <role>Study Director</role>
    <affiliation>Cidara Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Mena</last_name>
    <phone>(858) 888-7868</phone>
    <email>clinicaltrialinfo@cidara.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan Lee</last_name>
    <phone>(858) 888-7868</phone>
    <email>clinicaltrialinfo@cidara.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California - Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stamford Hospital</name>
      <address>
        <city>Stanford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy Health - St. Vincent Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reading Hospital and Medical Center</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Tech, Carillion School of Medicine</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sveti Ivan Rilski&quot;, Sofia, Clinic of Clinical Hematology</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Clinic of Hematology, Department of Clinical Hematology</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital &quot;Attikon&quot;, 2nd Department of Critical Care</name>
      <address>
        <city>Athens</city>
        <state>Chaidari</state>
        <zip>12 462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Larissa, Department of Critical Care Unit</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Evangelismos&quot;, 5th Department of Internal Medicine and Infectious Diseases Unit</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laikon General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IASO General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>155 62</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Evangelismos&quot;, Department of Critical Care</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polyclinic S. Orsola-Malpighi, Department of Organ Impairment and Transplants, Operative Unit of Infectious Diseases</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Polyclinic Hospital of Modena, Department of General and Specialist Surgery, Operative Unit of Anesthesia and Intensive Care I</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Pisa, Department of Gastroenterology and Infectious Diseases, Operative Unit of Infectious Diseases</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Polyclinic Agostino Gemelli, Complex Operative Unit of Infectious Diseases 2</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital &quot;Santa Maria della Misericordia&quot; of Udine, Department of Specialist Medicine, Clinic of Infectious Diseases</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Nuestra Senora de Valme,</name>
      <address>
        <city>Seville</city>
        <state>Andalusia</state>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen del Rocio (HUVR)</name>
      <address>
        <city>Seville</city>
        <state>Andalusia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Cruces, Unit of Infectious Diseases</name>
      <address>
        <city>Bizkaia</city>
        <state>Barakaldo</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Vall d'Hebron (HUVH), Department of Infectious Diseases</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona, Department of Infectious Diseases</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar, Department of Infectious Diseases</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General University Hospital Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Clinical San Carlos, Department of Microbiology</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 23, 2017</lastchanged_date>
  <firstreceived_date>March 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mycoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Candidemia</mesh_term>
    <mesh_term>Fungemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
